Zydus Lifesciences Unveils Breakthrough Drug for Transplant Patients

Zydus Lifesciences on Wednesday said it has launched ANVIMO, a breakthrough medication for the prevention of Cytomegalovirus infection for haematopoietic stem cell transplant and kidney transplant patients. ANVIMO (Letermovir) will be available in dosages of 240 mg and 480 mg, the drug firm said in a statement. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes.

""The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering world-class healthcare solutions,"" Zydus Lifesciences MD Sharvil Patel stated.
Transplantation is a life-saving but financially burdensome procedure in India. The high cost of post-transplant care, particularly CMV prophylaxis, adds to the burden. Until now, innovator Letermovir 240 mg was imported at over Rs 5 lakh per month, severely limiting access.

With the launch of ANVIMO, Zydus said it has significantly reduced the cost by 91 per cent of the innovator price, making treatment of CMV prophylaxis significantly more affordable for Indian patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!